Abstract
Amorphous peroxotitantes (APT) are insoluble titanium-based particles that bind a variety of metal compounds with high affinity; these particles could be sequestered locally in a solid phase to deliver metal-based drugs. Previous studies have confirmed the 'biodelivery' of metals from metal-APT complexes to fibroblasts, but not monocytes. Our goal in the current study was to use monocytic cytokine secretion to assess delivery of gold or platinum-based compounds from APT to human THP1 monocytes. Cytokine secretion was not triggered by APT alone or metal-APT complexes. In monocytes activated by lipopolysaccharide (LPS), APT alone enhanced or suppressed IL1beta or IL6 secretion, yet TNFalpha secretion was unaffected. Complexes of APT and Au(III) or cis-platin altered LPS-activated IL6 or IL1beta secretion most, TNFalpha least. Our results suggest that the APT deliver metals to monocytes.
Publication types
-
Evaluation Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Biocompatible Materials / pharmacokinetics
-
Biocompatible Materials / pharmacology
-
Cells, Cultured
-
Cisplatin / administration & dosage
-
Cisplatin / pharmacokinetics
-
Drug Carriers / pharmacokinetics
-
Drug Carriers / pharmacology
-
Drug Delivery Systems*
-
Fibroblasts / drug effects
-
Fibroblasts / metabolism
-
Gold / pharmacokinetics
-
Gold / pharmacology
-
Humans
-
Interleukin-6 / metabolism
-
Ions / administration & dosage
-
Ions / pharmacokinetics*
-
Lipopolysaccharides / pharmacology
-
Materials Testing
-
Metals / administration & dosage
-
Metals / pharmacokinetics*
-
Monocytes / drug effects
-
Monocytes / metabolism*
-
Oxides / pharmacokinetics
-
Oxides / pharmacology
-
Titanium / pharmacokinetics*
-
Titanium / pharmacology
-
Tumor Necrosis Factor-alpha / metabolism
Substances
-
Biocompatible Materials
-
Drug Carriers
-
Interleukin-6
-
Ions
-
Lipopolysaccharides
-
Metals
-
Oxides
-
Tumor Necrosis Factor-alpha
-
peroxo-titanate
-
Gold
-
Titanium
-
Cisplatin